vs
Side-by-side financial comparison of ATLANTIC AMERICAN CORP (AAME) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $53.8M, roughly 1.1× ATLANTIC AMERICAN CORP). ATLANTIC AMERICAN CORP runs the higher net margin — 1.1% vs -92.6%, a 93.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 20.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 7.2%).
The Atlantic Telegraph Company was a company formed on 6 November 1856 to undertake and exploit a commercial telegraph cable across the Atlantic Ocean, the first such telecommunications link.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
AAME vs RYTM — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $53.8M | $60.1M |
| Net Profit | $577.0K | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 1.4% | -87.1% |
| Net Margin | 1.1% | -92.6% |
| Revenue YoY | 20.8% | 83.8% |
| Net Profit YoY | 128.9% | — |
| EPS (diluted) | $0.02 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | $53.8M | $51.3M | ||
| Q2 25 | $55.3M | $48.5M | ||
| Q1 25 | $50.1M | $32.7M | ||
| Q4 24 | $49.0M | $41.8M | ||
| Q3 24 | $44.5M | $33.3M | ||
| Q2 24 | $47.7M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $577.0K | $-52.9M | ||
| Q2 25 | $3.3M | $-46.6M | ||
| Q1 25 | $802.0K | $-49.5M | ||
| Q4 24 | $412.0K | $-43.3M | ||
| Q3 24 | $-2.0M | $-43.6M | ||
| Q2 24 | $-684.0K | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | 1.4% | -102.6% | ||
| Q2 25 | 7.6% | -93.4% | ||
| Q1 25 | 2.1% | -143.7% | ||
| Q4 24 | 1.1% | -98.6% | ||
| Q3 24 | -5.5% | -132.0% | ||
| Q2 24 | -1.8% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | 1.1% | -103.1% | ||
| Q2 25 | 6.0% | -96.1% | ||
| Q1 25 | 1.6% | -151.4% | ||
| Q4 24 | 0.8% | -103.6% | ||
| Q3 24 | -4.5% | -131.2% | ||
| Q2 24 | -1.4% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $0.02 | $-0.82 | ||
| Q2 25 | $0.15 | $-0.75 | ||
| Q1 25 | $0.03 | $-0.81 | ||
| Q4 24 | $0.01 | $-0.71 | ||
| Q3 24 | $-0.10 | $-0.73 | ||
| Q2 24 | $-0.04 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.4M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $109.5M | $122.9M |
| Total Assets | $430.9M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | $34.4M | $416.1M | ||
| Q2 25 | $46.4M | $291.0M | ||
| Q1 25 | $35.9M | $314.5M | ||
| Q4 24 | $35.6M | $320.6M | ||
| Q3 24 | $23.0M | $298.4M | ||
| Q2 24 | $21.2M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | $109.5M | $148.8M | ||
| Q2 25 | $106.2M | $-11.9M | ||
| Q1 25 | $102.4M | $18.9M | ||
| Q4 24 | $99.6M | $21.7M | ||
| Q3 24 | $105.8M | $11.2M | ||
| Q2 24 | $100.7M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | $430.9M | $506.9M | ||
| Q2 25 | $429.3M | $372.7M | ||
| Q1 25 | $388.4M | $386.7M | ||
| Q4 24 | $393.4M | $392.3M | ||
| Q3 24 | $387.0M | $363.6M | ||
| Q2 24 | $386.0M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | — |
| Free Cash FlowOCF − Capex | $6.6M | — |
| FCF MarginFCF / Revenue | 12.3% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 11.51× | — |
| TTM Free Cash FlowTrailing 4 quarters | $19.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-25.4M | ||
| Q3 25 | $6.6M | $-26.6M | ||
| Q2 25 | $9.3M | $-23.3M | ||
| Q1 25 | $-722.0K | $-40.4M | ||
| Q4 24 | $4.8M | $-18.8M | ||
| Q3 24 | $90.0K | $-25.2M | ||
| Q2 24 | $416.0K | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $6.6M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $-986.0K | — | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $58.0K | — | ||
| Q2 24 | $361.0K | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.3% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 9.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.51× | — | ||
| Q2 25 | 2.80× | — | ||
| Q1 25 | -0.90× | — | ||
| Q4 24 | 11.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAME
| Bankers Fidelity | $30.0M | 56% |
| American Southern | $23.7M | 44% |
RYTM
Segment breakdown not available.
